Corrigendum to "Cytostatic drugs differentially affect phenotypic features of porcine coronary artery smooth muscle cell populations" [FEBS Lett. 581 (2007) 5847-5851] (DOI:10.1016/j.febslet.2007.11.060);Cytostatic drugs differentially affect phenotypic features of porcine coronary artery smooth muscle cell populations

FEBS Letters

Volumn 581, Issue 30, 2007, Pages 5847-5851

  Prunotto, Marco ^a,b   Bacchetta, Marc ^a   Jayaraman, Swaminathan ^c   Galloni, Marco ^b   Van Eys, Guillaume ^d   Gabbiani, Giulio ^a   Bochaton Piallat, Marie Luce ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b UNIVERSITY OF TURIN   (Italy)

^c Vascular Concept   (United Kingdom)

^d MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Curcumin; Cyclosporine; Imatinib; Rapamycin; S100A4; Smoothelin

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CALVASCULIN; CURCUMIN; CYCLOSPORIN A; IMATINIB; RAPAMYCIN; SMOOTHELIN; UROKINASE;

ANIMAL CELL; ARTERY INTIMA PROLIFERATION; ARTICLE; CELL ACTIVITY; CELL DIFFERENTIATION; CELL MIGRATION; CELL POPULATION; CELL PROLIFERATION; CONTROLLED STUDY; CORONARY ARTERY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESTENOSIS; SMOOTH MUSCLE FIBER; SPINDLE CELL; SWINE;

SUS;

EID: 37049008918     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2008.01.057     Document Type: Erratum

References (22)

1. Birkenhauer P., Yang Z., and Gander B. Preventing restenosis in early drug-eluting stent era: recent developments and future perspectives. J. Pharm. Pharmacol. 56 (2004) 1339-1356
2. Serruys P.W., Kutryk M.J., and Ong A.T. Coronary-artery stents. N. Engl. J. Med. 354 (2006) 483-495
3. Stepkowski S.M. Molecular targets for existing and novel immunosuppressive drugs. Expert Rev. Mol. Med. 2000 (2000) 1-23
4. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., Zimmermann J., and Lydon N.B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2 (1996) 561-566
5. Demetri G.D., von Mehren M., Blanke C.D., Van den Abbeele A.D., Eisenberg B., Roberts P.J., Heinrich M.C., Tuveson D.A., Singer S., Janicek M., Fletcher J.A., Silverman S.G., Silberman S.L., Capdeville R., Kiese B., Peng B., Dimitrijevic S., Druker B.J., Corless C., Fletcher C.D., and Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347 (2002) 472-480
6. Myllarniemi M., Calderon L., Lemstrom K., Buchdunger E., and Hayry P. Inhibition of platelet-derived growth factor receptor tyrosine kinase inhibits vascular smooth muscle cell migration and proliferation. FASEB J. 11 (1997) 1119-1126
7. Chen H.W., and Huang H.C. Effect of curcumin on cell cycle progression and apoptosis in vascular smooth muscle cells. Br. J. Pharmacol. 124 (1998) 1029-1040
8. Yang X., Thomas D.P., Zhang X., Culver B.W., Alexander B.M., Murdoch W.J., Rao M.N., Tulis D.A., Ren J., and Sreejayan N. Curcumin inhibits platelet-derived growth factor-stimulated vascular smooth muscle cell function and injury-induced neointima formation. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 85-90
9. Ross R. Atherosclerosis: an inflammatory disease. N. Engl. J. Med. 340 (1999) 115-126
10. Hao H., Gabbiani G., and Bochaton-Piallat M.L. Arterial smooth muscle cell heterogeneity: implications for atherosclerosis and restenosis development. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 1510-1520
11. Hao H., Ropraz P., Verin V., Camenzind E., Geinoz A., Pepper M.S., Gabbiani G., and Bochaton-Piallat M.L. Heterogeneity of smooth muscle cell populations cultured from pig coronary artery. Arterioscler. Thromb. Vasc. Biol. 22 (2002) 1093-1099
12. Brisset A.C., Hao H., Camenzind E., Bacchetta M., Geinoz A., Sanchez J.C., Chaponnier C., Gabbiani G., and Bochaton-Piallat M.L. Intimal smooth muscle cells of porcine and human coronary artery express S100A4, a marker of the rhomboid phenotype in vitro. Circ. Res. 100 (2007) 1055-1062
13. Skalli O., Ropraz P., Trzeciak A., Benzonana G., Gillessen D., and Gabbiani G. A monoclonal antibody against alpha-smooth muscle actin: a new probe for smooth muscle differentiation. J. Cell Biol. 103 (1986) 2787-2796
14. van der Loop F.T., Schaart G., Timmer E.D., Ramaekers F.C., and van Eys G.J. Smoothelin, a novel cytoskeletal protein specific for smooth muscle cells. J. Cell Biol. 134 (1996) 401-411
15. Li L., Blumenthal D.K., Masaki T., Terry C.M., and Cheung A.K. Differential effects of imatinib on PDGF-induced proliferation and PDGF receptor signaling in human arterial and venous smooth muscle cells. J. Cell Biochem. 99 (2006) 1553-1563
16. Dudley A., Gilbert R.E., Thomas D., Cox A., Price J.T., Best J., and Jenkins A. STI-571 inhibits in vitro angiogenesis. Biochem. Biophys. Res. Commun. 310 (2003) 135-142
17. Hacker T.A., Griffin M.O., Guttormsen B., Stoker S., and Wolff M.R. Platelet-derived growth factor receptor antagonist STI571 (imatinib mesylate) inhibits human vascular smooth muscle proliferation and migration in vitro but not in vivo. J. Invasive Cardiol. 19 (2007) 269-274
18. Owens G.K., Kumar M.S., and Wamhoff B.R. Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol. Rev. 84 (2004) 767-801
19. van Eys G.J., Niessen P.M., and Rensen S.S. Smoothelin in vascular smooth muscle cells. Trends Cardiovasc. Med. 17 (2007) 26-30
20. Poon M., Marx S.O., Gallo R., Badimon J.J., Taubman M.B., and Marks A.R. Rapamycin inhibits vascular smooth muscle cell migration. J. Clin. Invest. 98 (1996) 2277-2283
21. Suzuki T., Kopia G., Hayashi S., Bailey L.R., Llanos G., Wilensky R., Klugherz B.D., Papandreou G., Narayan P., Leon M.B., Yeung A.C., Tio F., Tsao P.S., Falotico R., and Carter A.J. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 104 (2001) 1188-1193
22. Carter A.J., Aggarwal M., Kopia G.A., Tio F., Tsao P.S., Kolata R., Yeung A.C., Llanos G., Dooley J., and Falotico R. Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. Cardiovasc. Res. 63 (2004) 617-624